Trial Outcomes & Findings for An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies (NCT NCT05433090)
NCT ID: NCT05433090
Last Updated: 2026-03-31
Results Overview
Retention rate is the percentage of consented patients who completed the ACP intervention visit. A retention rate of \>70% was considered feasible.
COMPLETED
NA
41 participants
From consent until completion of the ACP intervention visit, usually within 1 week.
2026-03-31
Participant Flow
Eligible patients being managed in the inpatient setting at the University of Rochester Medical Center (URMC) Wilmot Cancer Institute (WCI), were identified by treating physicians, APPs, hematology/oncology fellows, nurses, and study coordinators. Patients were recruited from November 2022 to October 2024.
57 patients were approached, and 41 consented (consent rate: 71.9%). The most common reasons patients declined to participate were a reluctance to complete surveys (n=8), feeling overwhelmed by their current situation (n=5), or a belief that discussing their preferences with the care team would not be helpful (n=3).
Participant milestones
| Measure |
Advanced Care Planning
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Overall Study
STARTED
|
41
|
|
Overall Study
Completed ACP Intervention
|
38
|
|
Overall Study
COMPLETED
|
35
|
|
Overall Study
NOT COMPLETED
|
6
|
Reasons for withdrawal
| Measure |
Advanced Care Planning
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Overall Study
Patient Discharged Before ACP Intervention
|
3
|
|
Overall Study
Withdrawal by Subject
|
1
|
|
Overall Study
Death
|
2
|
Baseline Characteristics
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
Baseline characteristics by cohort
| Measure |
Advanced Care Planning
n=41 Participants
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Age, Continuous
|
68 Years
STANDARD_DEVIATION 4.3 • n=4 Participants
|
|
Sex: Female, Male
Female
|
22 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
19 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
41 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
40 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=4 Participants
|
|
Education
High school or below
|
12 Participants
n=4 Participants
|
|
Education
Training after high school or some college/university
|
12 Participants
n=4 Participants
|
|
Education
College/University graduate
|
11 Participants
n=4 Participants
|
|
Education
Post Graduate level
|
5 Participants
n=4 Participants
|
|
Education
Other
|
1 Participants
n=4 Participants
|
|
Marital status
Married/long term, committed significant other
|
24 Participants
n=4 Participants
|
|
Marital status
Divorced
|
3 Participants
n=4 Participants
|
|
Marital status
Single
|
5 Participants
n=4 Participants
|
|
Marital status
Widowed
|
9 Participants
n=4 Participants
|
|
Employment status
Employed
|
10 Participants
n=4 Participants
|
|
Employment status
Retired
|
28 Participants
n=4 Participants
|
|
Employment status
Unemployed
|
1 Participants
n=4 Participants
|
|
Employment status
Homemaker
|
0 Participants
n=4 Participants
|
|
Employment status
Other
|
2 Participants
n=4 Participants
|
|
Caregiver living with the patient
Partner (spouse/significant other)
|
25 Participants
n=4 Participants
|
|
Caregiver living with the patient
Child/children
|
1 Participants
n=4 Participants
|
|
Caregiver living with the patient
None
|
15 Participants
n=4 Participants
|
|
Caregiver not living with the patient
Partner (spouse/significant other)
|
5 Participants
n=4 Participants
|
|
Caregiver not living with the patient
Child/children
|
8 Participants
n=4 Participants
|
|
Caregiver not living with the patient
Other relative(s)
|
2 Participants
n=4 Participants
|
|
Caregiver not living with the patient
None
|
26 Participants
n=4 Participants
|
|
Cancer diagnosis
Acute lymphoblastic leukemia
|
3 Participants
n=4 Participants
|
|
Cancer diagnosis
Acute myeloid leukemia
|
25 Participants
n=4 Participants
|
|
Cancer diagnosis
Central Nervous System Lymphoma
|
1 Participants
n=4 Participants
|
|
Cancer diagnosis
Lymphoma
|
3 Participants
n=4 Participants
|
|
Cancer diagnosis
Multiple myeloma
|
4 Participants
n=4 Participants
|
|
Cancer diagnosis
Myelodysplastic syndrome
|
4 Participants
n=4 Participants
|
|
Cancer diagnosis
Plasma cell leukemia
|
1 Participants
n=4 Participants
|
|
Cancer diagnosis duration
<6 months
|
24 Participants
n=4 Participants
|
|
Cancer diagnosis duration
>= 6 months
|
17 Participants
n=4 Participants
|
|
Cancer health literacy
Adequate literacy
|
39 Participants
n=4 Participants
|
|
Cancer health literacy
Limited literacy
|
2 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: From consent until completion of the ACP intervention visit, usually within 1 week.Population: All consented participants who underwent baseline assessment.
Retention rate is the percentage of consented patients who completed the ACP intervention visit. A retention rate of \>70% was considered feasible.
Outcome measures
| Measure |
Advanced Care Planning
n=41 Participants
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Retention Rate
Retained - completed ACP intervention
|
38 Participants
|
|
Retention Rate
Not retained - didn't complete ACP intervention
|
3 Participants
|
SECONDARY outcome
Timeframe: From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.Population: All participants who consented and completed baseline measures. Baseline and post-intervention data represent paired data from the same participants who completed both timepoints.
Data on the patient's completion of scanned healthcare proxy form that was completed with their physician was collected via the electronic medical record. This is expressed as a percentage.
Outcome measures
| Measure |
Advanced Care Planning
n=41 Participants
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Advance Directive Completion - HCP
Baseline · HCP Completed
|
23 Participants
|
|
Advance Directive Completion - HCP
Baseline · HCP Not Completed
|
18 Participants
|
|
Advance Directive Completion - HCP
After ACP Intervention · HCP Completed
|
31 Participants
|
|
Advance Directive Completion - HCP
After ACP Intervention · HCP Not Completed
|
10 Participants
|
SECONDARY outcome
Timeframe: From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.Population: All participants who consented and completed baseline measures. Baseline and post-intervention data represent paired data from the same participants who completed both timepoints.
Data on the patient's completion of scanned medical order for life sustaining treatment (MOLST) form that was completed with their clinician was collected via the electronic medical record. This is expressed as a percentage.
Outcome measures
| Measure |
Advanced Care Planning
n=41 Participants
This is a single-arm pilot study. After completing baseline measures, all patients received an inpatient Advanced Care Planning (ACP) intervention. Before the visit, patients received a preparation pamphlet. The APP/hematology/oncology fellow used the "Serious Illness Care Guide" during the ACP intervention to discuss advanced care planning and end of life care with the patient. At the end of the visit, patients received a "Family Guide" to help communicate with their family about the visit.
|
|---|---|
|
Advance Directive Completion - MOLST
Baseline · MOLST Completed
|
7 Participants
|
|
Advance Directive Completion - MOLST
Baseline · MOLST Not Completed
|
34 Participants
|
|
Advance Directive Completion - MOLST
After ACP Intervention · MOLST Completed
|
20 Participants
|
|
Advance Directive Completion - MOLST
After ACP Intervention · MOLST Not Completed
|
21 Participants
|
Adverse Events
Advanced Care Planning
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place